ストックスクリーナーアプリを入手
3.06
3.73%
0.11
Anixa Biosciences Inc (ANIX) 最新ニュース
Anixa Biosciences, Inc Receives Notice of Allowance from Chinese National Intellectual Property Administration for Patent Covering Breast Cancer Vaccine Technology - MarketScreener
Anixa biosciences secures Chinese patent for breast cancer vaccine - Investing.com
First-Ever Chinese Patent Granted: Anixa's Revolutionary Breast Cancer Vaccine Targets World's Largest Market - Stock Titan
Anixa Biosciences: Buy Rating Reiterated, Price Target Raised to $10 - AInvest
Anixa Biosciences shares rise 1.89% intraday after treating second patient in fourth cohort of ovarian cancer CAR-T clinical trial. - AInvest
Anixa Biosciences treats second patient in fourth ovarian cancer trial cohort - TipRanks
30x Dose Increase Shows No Toxicity: Anixa's Novel Ovarian Cancer CAR-T Therapy Reaches Major Milestone - Stock Titan
Can Anixa Biosciences Inc. continue delivering strong returns2025 Technical Patterns & High Return Trade Opportunity Guides - thegnnews.com
Combining price and volume data for Anixa Biosciences Inc.2025 Trade Ideas & Technical Buy Zone Confirmations - Newser
Is this a good reentry point in Anixa Biosciences Inc.2025 Geopolitical Influence & AI Forecast for Swing Trade Picks - Newser
Is Anixa Biosciences Inc. benefiting from interest rate changesJuly 2025 Trade Ideas & Proven Capital Preservation Tips - thegnnews.com
Will Anixa Biosciences Inc. outperform the market in YEAR2025 Market Outlook & Fast Exit Strategy with Risk Control - thegnnews.com
Anixa Biosciences Inc. May Be Forming Higher Low — Chartwatchers Alert2025 Volatility Report & Community Verified Trade Alerts - sundaytimes.kr
Anixa Biosciences Bets On Cancer Vaccines And CAR-T Trials - Finimize
Can Anixa Biosciences Inc. sustain its profitabilityJuly 2025 PostEarnings & Free Community Consensus Stock Picks - thegnnews.com
Anixa Biosciences Inc. Forms Bullish Flag — Upside Ahead2025 Top Gainers & Weekly Breakout Opportunity Watchlist - sundaytimes.kr
Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology - BioSpace
Anixa Biosciences Receives Patent Extension for CAR-T Technology - AInvest
Solid Biosciences shares rise 2.81% after-hours following Anixa Biosciences' patent extension to 2045. - AInvest
Anixa Biosciences Receives Additional US Patent for CAR-T Technology, Extending Protection to 2045 - AInvest
Anixa Biosciences secures new patent for solid tumor CAR-T technology - Investing.com India
Anixa Biosciences secures new patent for solid tumor CAR-T technology By Investing.com - Investing.com South Africa
Anixa Biosciences Announces Issuance Of Additional U.S. Patent For CAR-T Technology - Barchart.com
Tools to assess Anixa Biosciences Inc.’s risk profileFree Profit Target Stock Opportunity Monitor - Newser
Anixa Biosciences shares rise 1.68% after-hours as Dr. Wenham to present at Ovarcoming Cancer Conference. - AInvest
Anixa Biosciences Announces Dr. Robert Wenham will speak about Immunotherapy in surviving Ovarian Cancer at the 13th Annual Ovarcoming Cancer Conference - The Malaysian Reserve
Breakthrough CAR-T Therapy for Ovarian Cancer: Moffitt's Chair Reveals Latest Trial Progress at Major Conference - Stock Titan
What momentum shifts mean for Anixa Biosciences Inc.Free Daily Volume Spike Trading Signals - Newser
D. Boral Capital Reaffirms “Buy” Rating for Anixa Biosciences (NASDAQ:ANIX) - Defense World
Competitive Positioning of Anixa Biosciences Inc.: Is It Leading or LaggingPortfolio Positioning Strategy With Timing - Newser
Anixa Biosciences Announces Commencement of US FDA Approved IND Transfer to Support Upcoming Phase 2 Breast Cancer Vaccine Trial - BioSpace
Director Makes Bold Move with Major Stock Purchase in Anixa Biosciences - TipRanks
Anixa Biosciences: Promising Developments and Strong Intellectual Property Bolster Buy Rating - TipRanks
Anixa plans to begin Phase 2 of breast cancer vaccine trial - TipRanks
Anixa Biosciences director Titterton buys $30k in stock By Investing.com - Investing.com Canada
Anixa Biosciences director Titterton buys $30k in stock - Investing.com India
Breakthrough Breast Cancer Vaccine Achieves 70% Immune Response, FDA Clears Path for Phase 2 Trial - Stock Titan
How does Anixa Biosciences Inc. compare to its industry peersStrong return on assets - Jammu Links News
What is Anixa Biosciences Inc. company’s growth strategyTriple-digit growth rates - Jammu Links News
How many analysts rate Anixa Biosciences Inc. as a “Buy”Turn volatility into profit opportunities - Jammu Links News
Is Anixa Biosciences Inc. stock overvalued or undervaluedTurn volatility into profit opportunities - Jammu Links News
What is the dividend policy of Anixa Biosciences Inc. stockCapitalize on momentum stocks early - Jammu Links News
What are analysts’ price targets for Anixa Biosciences Inc. in the next 12 monthsDiscover high-impact stocks for your portfolio - Jammu Links News
What are the technical indicators suggesting about Anixa Biosciences Inc.Free Investment Risk Control - Jammu Links News
When is Anixa Biosciences Inc. stock expected to show significant growthExplosive returns - Jammu Links News
Why is Anixa Biosciences Inc. stock attracting strong analyst attentionGet real-time updates on market movers - Jammu Links News
Should I hold or sell Anixa Biosciences Inc. stock in 2025Turn volatility into profit opportunities - Jammu Links News
What catalysts could drive Anixa Biosciences Inc. stock higher in 2025Unlock powerful stock screening tools - Jammu Links News
How does Anixa Biosciences Inc. generate profit in a changing economyAchieve rapid growth with smart investments - Jammu Links News
RSI Crosses Above 30 for Anixa Biosciences Inc. — Reversal in SightWeekly Top Gainers Forecast Watchlist Released - metal.it
Anixa Biosciences Secures Canadian Patent for Breast Cancer Vaccine Technology - AInvest
Anixa Biosciences CEO Kumar buys $15,800 in stock - Investing.com Australia
Anixa Biosciences CEO Kumar buys $15,800 in stock By Investing.com - Investing.com Nigeria
Anixa Biosciences CEO Kumar Amit Buys 5,000 Shares at $3.16/Share. - AInvest
0.94%
1.72%
大文字化:
|
ボリューム (24 時間):